Biocytogen Deepens Acepodia Tie-Up With Option-Based Deal on Next-Gen Bispecific ADCs

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an announcement.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has expanded its collaboration with U.S.-based Acepodia Inc. through a newly signed option and license agreement to support the structured evaluation and potential licensing of two bispecific antibody-drug conjugate (BsADC) programs. Building on an existing co-development relationship, the deal gives Acepodia an option for exclusive worldwide rights to these programs and provides Biocytogen with an upfront option fee and the potential for further development, regulatory and commercial milestone payments, along with royalties on future sales, underscoring Biocytogen’s strategy to leverage its RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation technology to advance next-generation dual-payload bispecific ADCs that may address limitations of conventional ADC therapies while avoiding any notifiable or connected transaction implications under Hong Kong listing rules.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biopharmaceutical company focused on developing next-generation antibody-based therapies, leveraging proprietary platforms such as its RenLite® technology. The company operates in the biopharmaceutical and oncology drug development industry, concentrating on innovative modalities including bispecific antibodies and antibody-drug conjugates for global markets.

Average Trading Volume: 1,105,969

Technical Sentiment Signal: Hold

Current Market Cap: HK$14.25B

Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.